Company / Cash & Equivalents
West Pharmaceutical Services Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$791.3M
FY2025
5-year range
$484.6M / $894.3M
FY2021-FY2025
Trend
+63.3%
vs FY2024
Sector context
#34 of 148
Health Care
What the data says
West Pharmaceutical Services's cash & equivalents of $791M is higher than 77% of companies in the Health Care sector (FY2025). Cash & Equivalents returned to growth in FY2025 after 2 years of decline, reaching $791M.
Based on SEC 10-K filings.
$791M in FY2025 with a 5-year CAGR of +18.6%. Top quartile in the Health Care sector.
Declined from $854M to $791M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -4.0%
- 5-Year CAGR
- +18.6%
- 10-Year CAGR
- -
Sector benchmark
-32.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +18.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 63.3% year-over-year.
- Ranks #34 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $791.3M | +63.3% |
| FY2024 | $484.6M | -43.2% |
| FY2023 | $853.9M | -4.5% |
| FY2022 | $894.3M | +17.3% |
| FY2021 | $762.6M | +126.0% |
| FY2020 | $337.4M | -23.2% |
| FY2019 | $439.1M | +30.1% |
| FY2018 | $337.4M | +43.0% |
| FY2017 | $235.9M | -7.6% |
| FY2016 | $255.3M | +11.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026